reports
Form 8.3 - Apex Fundrock Limited : Re Tyman plc
Apex Fundrock Limited (MISL) Form 8.3 - Apex Fundrock Limited : Re Tyman plc 09-May-2024 / 12:41 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), s...
GN Store Nord: 1 director
A director at GN Store Nord bought 7,000 shares at 201.500DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Widodo Makmur Perkasa Tbk PT: 1 director
A director at Widodo Makmur Perkasa Tbk PT bought 375,000,000 shares at 15.000IDR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Arbona AB: 1 director
A director at Arbona AB sold 75,000 shares at 3.000SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Moody's Ratings affirms Daegu Bank's A2 ratings, changes outlook to ne...
Moody's Ratings (Moody's) has affirmed Daegu Bank, Ltd.'s A2 foreign-currency and local-currency long-term bank deposit ratings and changed their outlooks to negative from stable. At the same time, Moody's has affirmed Daegu Bank's baa1 Baseline Credit Assessment (BCA) and Adjusted BCA, the bank's...
Moody's Ratings affirms Daegu Bank's A2 ratings, changes outlook to ne...
MOODY'S INVESTORS SERVICE 1Moody's Ratings, 대구은행의 ‘A2’ 신용등급 재확인; 전망 ‘부정적’으로 조정 2024 년 5 월 9 일、 홍콩 、 한국어 보도자료는 영문 보도자료의 번역본입니다. 한국어와 영문 보도자료 간에 상이한 점이 있을 경우 영어 원문이 우선합니다.Moody’s Ratings(이하 ‘무디스’)는 대구은행의 ‘A2’ 외화표시 및 현지통화표시 장기 은행예금등급을 재확인하고, 전망을 종전의 ‘안정적’에서 ‘부정적’으로 조정하였다.동시에 무디스는 대구은행의 ‘baa1’ 독자신용도(BCA...
Swire Pacific Ltd: 1 director
A director at Swire Pacific Ltd sold 527,500 shares at 10.747HKD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
GFL Environmental Inc: 1 director
A director at GFL Environmental Inc sold/sold after exercising options 86,820 shares at 44.920CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
Installed Building Products Reports First Quarter 2024 Results; Declar...
COLUMBUS, Ohio--(BUSINESS WIRE)-- Installed Building Products, Inc. (the "Company" or "IBP") (NYSE: IBP), an industry-leading installer of insulation and complementary building products, today announced results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights (Comparisons are to Prior Year Period) Net revenue increased 5.1% to $692.9 million Installation revenue increased 5.3% to $655.9 million, as single-family and multi-family sales growth combined with sales from IBP's recent acquisitions Other revenue, which includes IBP’s manufacturing and distribution o...
Hilton Grand Vacations Reports First Quarter 2024 Results
ORLANDO, Fla.--(BUSINESS WIRE)-- Hilton Grand Vacations Inc. (NYSE: HGV) (“HGV” or “the Company”) today reports its first quarter 2024 results. First quarter of 2024 highlights1 Total contract sales were $631 million. Member count was 718,000. Net Owner Growth (NOG) for the legacy HGV-DRI business for the 12 months ended March 31, 2024, was 2%. Total revenues for the first quarter of 2024 were $1,156 million compared to $934 million for the same period in 2023. Total revenues were affected by a net recognition of $2 million in the current period compared to a net recognition of $4...
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 15, 2024Time: 3:05 p.m. ETLocation: New York, NY HCW BioConnect Conferenc...
Lexicon Pharmaceuticals to Participate in the Bank of America Securiti...
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET). A simultaneous webcast will be available in the “Events” section of the Lexicon website at , and a recording of the webcast will be available for two weeks following the original...
Whole Earth Brands Reports First Quarter 2024 Results
Whole Earth Brands Reports First Quarter 2024 Results CHICAGO, May 09, 2024 (GLOBE NEWSWIRE) -- Whole Earth Brands, Inc. (the “Company” or “we” or “our”) (Nasdaq: FREE), a global food company enabling healthier lifestyles through premium plant-based sweeteners, flavor enhancers and other foods, today announced its financial results for its first quarter ended March 31, 2024. First Quarter Highlights Consolidated revenue of $129.5 million, a decrease of 2.2% on a reported basis and 2.3% on a constant currency basis compared to the prior year period.Branded CPG revenue decreased 3.5% ...
Intellia Therapeutics Announces First Quarter 2024 Financial Results a...
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to review of IND application; expect to initiate the study by year-end Plan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 On track to initiate the Phase 3 study of NTLA-2002 ...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Resu...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financia...
Thérapeutique Knight déclare ses résultats du premier trimestre de 202...
Thérapeutique Knight déclare ses résultats du premier trimestre de 2024 MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), une société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.) de premier plan, a annoncé aujourd’hui ses résultats financiers pour le premier trimestre clos le 31 mars 2024. Tous les montants sont exprimés en milliers de dollars canadiens (sauf indication contraire), à l’exception du nombre d’actions et des montants par action. Faits saillants de 2024 Résultats financiers Produits des act...
Cronos Group Reports 2024 First Quarter Results
Cronos Group Reports 2024 First Quarter Results Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach® was top-3 in retail sales in Canada in the flower, edible, and vape categories in Q1 2024 Launched PEACE NATURALS® brand in the United Kingdom in May 2024 TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results. “Cron...
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results an...
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage imm...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financ...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation Tegoprubart used as part of immunosuppressive treatment following the first-ever kidney xenotransplant IRVINE, Calif., May 09,...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parki...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Compa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.